Abstract:ABCB1 is a promising therapeutic target for overcoming multidrug resistance (MDR). In this work, we reported the structure-based design of triazolo[1,5-a]pyrimidines as new ABCB1 modulators, of which WS-691 significantly increased sensitization of ABCB1-overexpressed SW620/Ad300 cells to paclitaxel (PTX) (IC50 = 22.02 nM). Mechanistic studies indicated that WS-691 significantly increased the intracellular concentration of PTX and [3H]-PTX while decreasing the efflux of [3H]-PTX in SW620/Ad300 cells by inhibiting the efflux function of ABCB1. The cellular thermal shift assay suggested that WS-691 could stabilize ABCB1 by directly binding to ABCB1. WS-691 could stimulate the activity of ABCB1 ATPase but had almost no inhibitory activity against CYP3A4. Importantly, WS-691 increased the sensitivity of SW620/Ad300 cells to PTX in vivo without observed toxicity. Collectively, WS-691 is a highly potent and orally active ABCB1 modulator capable of overcoming MDR. The triazolo[1,5-a]pyrimidine may be a promising scaffold for developing more potent ABCB1 modulators.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.0c01741?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01741</a>.Cell survival rates under the nontoxic concentration of compounds toward selected cancer cells NMR, HRMS, and HPLC spectra of compounds 5–55 (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01741/suppl_file/jm0c01741_si_001.pdf">PDF</a>)Coordinates of modeled structures in PDB format: WS-36 in complex with ABCB1 (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4Q9H">4Q9H</a>) (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01741/suppl_file/jm0c01741_si_002.pdb">PDB</a>)Coordinates of modeled structures in PDB format: WS-691 in complex with ABCB1 (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4Q9H">4Q9H</a>) (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01741/suppl_file/jm0c01741_si_003.pdb">PDB</a>)Molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01741/suppl_file/jm0c01741_si_004.csv">CSV</a>)This article has not yet been cited by other publications.

Imidazo[1,2-a]Pyridine Derivatives As Novel Dual-Target Inhibitors of ABCB1 and ABCG2 for Reversing Multidrug Resistance.

Imidazo[1,2-a]Pyridine Derivatives as Novel Dual-Target Inhibitors of ABCB1 and ABCG2 for Resistance

Design, synthesis, and biological evaluation of phenylurea indole derivatives as ABCG2 inhibitors

Discovery of 5-Cyano-6-phenylpyrimidin Derivatives Containing an Acylurea Moiety As Orally Bioavailable Reversal Agents Against P-Glycoprotein-Mediated Mutidrug Resistance.

Discovery of novel pyrazolo[1,5-a]pyrimidine derivatives as potent reversal agents against ABCB1-mediated multidrug resistance

2-Trifluoromethyl-2-Hydroxypropionamide Derivatives as Novel Reversal Agents of ABCG2 (BCRP)-Mediated Multidrug Resistance: Synthesis and Biological Evaluations

Exploration of 1,2,3-Triazole-pyrimidine Hybrids As Potent Reversal Agents Against ABCB1-mediated Multidrug Resistance

Design, Synthesis and Biological Evaluation of Biaryl Amide Derivatives As Modulators of Multi-Drug Resistance

Exploration of 2-((Pyridin-4-ylmethyl)amino)nicotinamide Derivatives As Potent Reversal Agents Against P-Glycoprotein-Mediated Multidrug Resistance.

Structure-Based Discovery of Pyrimidine Aminobenzene Derivatives as Potent Oral Reversal Agents against P-gp- and BCRP-Mediated Multidrug Resistance

Synthesis and evaluation of novel tetrahydroisoquinoline-benzo[ h ]chromen-4-one conjugates as dual ABCB1/CYP1B1 inhibitors for overcoming MDR in cancer

Discovery of (quinazolin-6-yl)benzamide derivatives containing a 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline moiety as potent reversal agents against P-glycoprotein-mediated multidrug resistance

Discovery of the Triazolo[1,5- a ]Pyrimidine-Based Derivative WS-898 as a Highly Efficacious and Orally Bioavailable ABCB1 Inhibitor Capable of Overcoming Multidrug Resistance

New Inhibitors of Breast Cancer Resistance Protein (ABCG2) Containing a 2,4-Disubstituted Pyridopyrimidine Scaffold

Design, Synthesis and Biological Evaluation of LBM-A5 Derivatives As Potent P-glycoprotein-mediated Multidrug Resistance Inhibitors.

Bipiperidinyl derivatives of 23-hydroxybetulinic acid reverse resistance of HepG2/ADM and MCF-7/ADR cells

Design, Synthesis and Biological Evaluation of N-(4-(2-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)ethyl)phenyl)-4-oxo-3,4-dihydrophthalazine-1-carboxamide Derivatives As Novel P-glycoprotein Inhibitors Reversing Multidrug Resistance

A Phenylfurocoumarin Derivative Reverses ABCG2-Mediated Multidrug Resistance In Vitro and In Vivo

Synthesis and Biological Evaluation of JL-A7 Derivatives As Potent ABCB1 Inhibitors.

Structure-Based Design, Synthesis, and Biological Evaluation of New Triazolo[1,5- a ]Pyrimidine Derivatives as Highly Potent and Orally Active ABCB1 Modulators

A Novel Synthetic Dihydroindeno[1,2-b] Indole Derivative (LS-2-3j) Reverses ABCB1- and ABCG2-Mediated Multidrug Resistance in Cancer Cells.